AKTIS ONCOLOGY ANNOUNCES PRESENTATION OF THE FIRST CLINICAL DATA SUPPORTING BROAD DEVELOPMENT OF A FIRST IN CLASS NECTIN-4 TARGETING RADIOPHARMACEUTICAL AKY-1189 AT 2024 EORTC-NCI-AACR SYMPOSIUM ON MOLECULAR TARGETS AND CANCER THERAPEUTICS ...Middle East

AKY-1189 is a novel Nectin-4 targeted radiopharmaceutical product candidate demonstrating substantial tumor uptake across several solid tumor types and is progressing in human development as a therapeutic agent AKY-1189 was engineered to deliver actinium-225 directly to tumors while...

Hence then, the article about aktis oncology announces presentation of the first clinical data supporting broad development of a first in class nectin 4 targeting radiopharmaceutical aky 1189 at 2024 eortc nci aacr symposium on molecular targets and cancer therapeutics was published today ( Friday 25/10/2024 - 01:12 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AKTIS ONCOLOGY ANNOUNCES PRESENTATION OF THE FIRST CLINICAL DATA SUPPORTING BROAD DEVELOPMENT OF A FIRST IN CLASS NECTIN-4 TARGETING RADIOPHARMACEUTICAL AKY-1189 AT 2024 EORTC-NCI-AACR SYMPOSIUM ON MOLECULAR TARGETS AND CANCER THERAPEUTICS )

Also on site :

• North Korea says its latest weapons tests included missiles with cluster-bomb warheads
• 1987 No. 1 Hit Ranked Among 'Best Hair Metal Songs of All Time' Became a Powerful Anthem for Starting Over
• Man rescued after two weeks trapped in collapsed Mexico mine